EVIDENT - Ebola Virus Disease: Correlates of protection, determinants of outcome, and clinical management

New EU research initiative to combat the Ebola epidemic in West Africa

In response to the Ebola epidemic in West Africa, a new H2020 EU research initiative ‘EVIDENT’ was launched on November 1st, 2014. The consortium, coordinated by Prof. Stephan Günther (Bernhard-Nocht-Institute for Tropical Medicine), comprises a multi-national team of experts from 11 partnering institutions. EVIDENT provides a research platform which builds upon the success of the European Mobile Laboratory consortium (EMLab) that is performing Ebola Virus Disease (EVD) diagnostics in affected West African countries since March 2014. EVIDENT’s mandate is to scientifically exploit specimens from EVD patients collected as part of the outbreak response in Guinea, Sierra Leone and Nigeria and to gather critical knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of Ebola Virus.

Equipped with a budget of € 1.7 million, the two-year EVIDENT project has clear objectives to combat current and future EVD epidemics: The research will provide a better understanding of the human immune response to Ebola virus. Results of this research will determine the suitability of blood derived from EVD survivors for use in EVD treatment and will give vaccine producers an opportunity to estimate the efficacy of vaccines. The initiative will also investigate how co-infections such as Malaria influence the course of EVD; this section of the study should improve supportive treatment and chances of survival. The EVIDENT consortium also plans to study the risk of virus transmission via patients' body fluids (e.g. urine, saliva). These results will play a role in determining the duration EVD patients need to be isolated. The evolution of the virus during the epidemic will be monitored and experimental systems will be established to examine the effects of genetic changes.

Information on pathophysiological and immunological changes generated by EVIDENT will eventually also facilitate the design of novel strategies for treatment of EVD.

Eurice is management partner of EVIDENT and thus contributes to the successful implementation of the goals of the project.

Your contact:
Dr. Birte Kretschmer
European Research and Project Office GmbH
Tel.:+49 30 37 4415 833
Email

Further reading

Tags: Horizon 2020